Jersey City-based Organon announced Sept. 18 it entered into an agreement to acquire Dermavant Sciences Ltd. in a $1.2 billion deal. The terms of the deal include an upfront payment of $175 million ...
Journey Medical Corp (NASDAQ:DERM) is one of the best performing micro cap stocks in 2025. On January 4, Lake Street analyst Thomas Flaten reaffirmed a Buy rating on Journey Medical Corp (NASDAQ:DERM) ...
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed ...
Pipeline advances in 2026 span a range of dermatology disease areas, including atopic dermatitis, hidradenitis suppurativa, and alopecia areata, with 3 ongoing PoC/Phase II clinical studies* and 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback